14.09

2.56% -0.37

After Hours: 13.92 -0.17 -1.21%

Corvus Pharmaceuticals Inc (CRVS)

Overview News Price History Option Chain Financials Discussions Forecast

Corvus Pharmaceuticals Inc stock is traded at $14.09, with a volume of 512.06K. It is down -2.56% in the last 24 hours and up +7.80% over the past month. Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Previous Close:

$14.46

Open:

$14.37

24h Volume:

512.06K

Relative Volume:

0.41

Market Cap:

$1.19B

Revenue:

Net Income/Loss:

$-44.17M

P/E Ratio:

-26.79

EPS:

-0.526

Net Cash Flow:

$-35.14M

1W Performance:

-5.50%

1M Performance:

+7.80%

6M Performance:

-20.93%

1Y Performance:

+153.87%

1-Day Range:

$13.79

$14.37

1-Week Range:

$13.79

$15.72

52-Week Range:

$5.28

$26.95

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name

Corvus Pharmaceuticals Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

(650) 900-4520

Address

901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

CRVS's Discussions on Twitter

Compare CRVS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVS Corvus Pharmaceuticals Inc	14.09	1.21B	0	-44.17M	-35.14M	-0.526
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	Goldman	Buy
Oct-13-25	Initiated	Barclays	Overweight
Jan-02-25	Initiated	H.C. Wainwright	Buy
Aug-18-23	Initiated	Oppenheimer	Outperform
Dec-01-21	Resumed	Jefferies	Buy
May-27-21	Initiated	Cantor Fitzgerald	Overweight
Feb-10-21	Downgrade	Mizuho	Buy → Neutral
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Credit Suisse	Outperform
Apr-18-16	Initiated	Guggenheim	Buy

View All

Corvus Pharmaceuticals Inc Stock (CRVS) Latest News

Aug 21, 2026

Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat

Aug 21, 2026

Aug 20, 2026

Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st

Aug 20, 2026

637,500 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by DCF Advisers LLC - MarketBeat

Aug 20, 2026

Aug 19, 2026

Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current UpdateFinancial Health Score - Vinanet

Aug 19, 2026

Aug 17, 2026

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - Yahoo Finance

Aug 17, 2026

Aug 16, 2026

Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap? - Sahm

Aug 16, 2026

Aug 15, 2026

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits

Aug 15, 2026

Aug 14, 2026

Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us

Aug 14, 2026

Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat

Aug 14, 2026

Aug 12, 2026

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail

Aug 12, 2026

Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha

Aug 12, 2026

HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat

Aug 12, 2026

Aug 11, 2026

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Aug 11, 2026

HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat

Aug 11, 2026

The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat

Aug 11, 2026

Aug 10, 2026

H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo

Aug 10, 2026

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha

Aug 10, 2026

Aug 09, 2026

Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm

Aug 09, 2026

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Aug 09, 2026

Aug 08, 2026

Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail

Aug 08, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Aug 08, 2026

Aug 07, 2026

Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com

Aug 07, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat

Aug 07, 2026

State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock Titan

Aug 07, 2026